Chimerix secures fast-track status for antiviral drug

03/14/2013 | Pharmaceutical Business Review Online

The FDA granted a fast-track status to Chimerix's CMX001 for prevention of cytomegalovirus infection. The drug previously received a fast-track designation for smallpox and adenoviral disease in post hematopoietic stem cell transplant patients. CMX001 prevents double-stranded DNA viruses from replicating.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA